(RTTNews) - Nevro Corp. (NVRO) announced receipt of FDA approval for expanded labeling for its Senza Spinal Cord Stimulation System for the treatment of Non-Surgical Refractory Back Pain. The approval is specific to Nevro's 10 kHz Therapy.
Keith Grossman, Chairman, Chief Executive Officer and President of Nevro, said: "This FDA approval marks another milestone in Nevro's commitment to expanding access to 10 kHz Therapy for these underserved patients. Nevro is now the only SCS company with specific, on-label indications for treating both NSRBP and Painful Diabetic Neuropathy patients."
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
